CD47 targeted therapies for the treatment of infectious disease
AssigneesThe Board of Trustees of the Leland Stanford Junior University, The United States of America, as represented by the Secretary, Department of Health and Human Services, The Regents of the University of California
InventorsKipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
Life of this patent
Estimating the term…
Abstract
Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRPα on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
Claims15
A method of treating a mammalian subject for intracellular pathogen infection, wherein the pathogen is a bacterium, the method comprising:
- administering to the subject an anti-CD47 agent that reduces the binding of CD47 on an infected cell to signal regulatory protein (SIRPa) on a phagocytic cell, at an effective dose for increasing the phagocytosis of the infected cell, wherein the anti-CD47 agent is:
- (a) an anti-CD47 antibody, (b) an anti-SIRPa antibody that does not stimulate signaling through SIRPa, (c) a soluble SIRPa polypeptide that specifically binds to CD47, or (d) a soluble CD47 polypeptide that specifically binds to SIRPa, wherein each of the anti-CD47 agent does not stimulate signaling through SIRPa expressed on phagocytic cell.
Dependencies are inferred from the claim text.